Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.

Marco Ladetto, Gloria Pagliano, Ilaria Avonto, Loredana Santo, Simone Ferrero, Federica Cavallo, Monica Astolfi, Patrizia Pregno, Claudia Crippa, Anna Marina Liberati, Vincenzo Callea, Luca De Rosa, Antonietta Falcone, Mariella Grasso, Daniela Drandi, Mario Boccadoro, Antonio Palumbo

Blood (2007) 110 (11): 530.

https://doi.org/10.1182/blood.V110.11.530.530

Published: 2007

Journal Articles

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Antonio Palumbo, MD, Alessandra Larocca, MD, Cecilia Rus, MD, Francesca Gay, MD, Davide Rossi, MD, Patrizia Pregno, MD, Patrizia Falco, MD, Ilaria Avonto, MD, Valeria Magarotto, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 2715.

https://doi.org/10.1182/blood.V110.11.2715.2715

Published: 2007

Journal Articles

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

Antonio Palumbo, MD, Ilaria Avonto, MD, Francesca Patriarca, MD, Claudia Crippa, MD, Maria T. Petrucci, MD, Fausto Rossini, MD, Paolo Corradini, MD, Anna M. Liberati, MD, Nicola Giuliani, MD, Norbert Pescosta, MD, Patrizia Falco, MD, Alessandra Larocca, MD, Paola Omedè, MD, Massimo Offidani, MD, Renato Fanin, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 448.

https://doi.org/10.1182/blood.V110.11.448.448

Published: 2007

Journal Articles

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Antonio Palumbo, Maria Teresa Ambrosini, Giulia Benevolo, Patrizia Pregno, Norbert Pescosta, Vincenzo Callea, Clotilde Cangialosi, Tommaso Caravita, Fortunato Morabito, Pellegrino Musto, Sara Bringhen, Patrizia Falco, Ilaria Avonto, Federica Cavallo, Mario Boccadoro, for the Italian Multiple Myeloma Network, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA)

Blood (2006) 109 (7): 2767–2772.

https://doi.org/10.1182/blood-2006-08-042275

Published: 2006

Journal Articles

Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.

Marco Ladetto, Monica Astolfi, Loredana Santo, Ilaria Avonto, Federica Cavallo, Gloria Pagliano, Patrizia Pregno, Mariella Grasso, Anna Marina Liberati, Tommaso Caravita, Francesco Pisani, Tommasina Guglielmelli, Elisa Genuardi, Rossana Crivelli, Carmen Cristiano, Daniela Drandi, Mario Boccadoro, Antonio Palumbo

Blood (2006) 108 (11): 3100.

https://doi.org/10.1182/blood.V108.11.3100.3100

Published: 2006

Journal Articles

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Antonio Palumbo, MD, Cecilia Rus, MD, Davide Rossi, MD, Patrizia Pregno, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3560.

https://doi.org/10.1182/blood.V108.11.3560.3560

Published: 2006

Journal Articles

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Antonio Palumbo, MD, Sara Bringhen, MD, Patrizia Falco, MD, Cecilia Rus, MD, Federica Cavallo, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Gabriele Gallone, MD, Tommaso Caravita, MD, Benedetto Bruno, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3562.

https://doi.org/10.1182/blood.V108.11.3562.3562

Published: 2006

Journal Articles

Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.

Antonio Palumbo, MD, Maria Teresa Ambrosini, MD, Patrizia Pregno, MD, Norbert Pescosta, MD, Vincenzo Callea, MD, Clotilde Cangialosi, MD, Tommaso Caravita, MD, Fortunato Morabito, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Patrizia Falco, MD, Sara Bringhen, MD, Mario Boccadoro, MD

Blood (2005) 106 (11): 2553.

https://doi.org/10.1182/blood.V106.11.2553.2553

Published: 2005

Journal Articles

Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Blood (2005) 106 (11): 779.

https://doi.org/10.1182/blood.V106.11.779.779

Published: 2005

Journal Articles

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Antonio Palumbo, MD, Patrizia Falco, MD, Pellegrino Musto, MD, Paolo Corradini, MD, Francesco Di Raimondo, MD, Giuseppe Rossi, MD, Nicola Giuliani, MD, Fortunato Morabito, MD, Annalisa Luraschi, MD, Antonietta Falcone, MD, Paola Omedè, PhD, Francesca Gay, MD, Ilaria Avonto, MD, Maria Teresa Ambrosini, MD, Sara Bringhen, MD, Jerome Zeldis, MD, Robert Knight, MD, Mario Boccadoro, MD, Maria Teresa Petrucci, MD

Blood (2005) 106 (11): 785.

https://doi.org/10.1182/blood.V106.11.785.785

Published: 2005

Journal Articles

Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant.

Antonio Palumbo, MD, Patrizia Falco, MD, Maria Teresa Ambrosini, MD, Tommaso Caravita, MD, Pellegrino Musto, MD, Maria Teresa Petrucci, MD, Patrizia Pregno, MD, Ilaria Avonto, MD, Alessandra Bertola, MD, Sara Bringhen, MD, Federica Cavallo, MD, Giovannino Ciccone, MD, Mario Boccadoro, MD

Blood (2004) 104 (11): 2396.

https://doi.org/10.1182/blood.V104.11.2396.2396

Published: 2004

NARROW

Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients.

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m 2 in Elderly Newly Diagnosed Patients: An Interim Analysis.

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR.

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy.

Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma.

Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma.

Oral Revlimid R Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma.

Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only